Leukemia Trial Results
- Nilotinib Effective and Safe in Initial Treatment of Chronic Leukemia
(Posted: 12/28/2009, Updated: 09/06/2011) - Preliminary results from a phase III trial testing nilotinib (Tasigna) against imatinib mesylate (Gleevec) as first-line treatment for chronic-phase chronic myelogenous leukemia (CML) indicate that nilotinib is effective and safe as initial treatment for this disease.
- Rituximab Improves Outcomes for Patients With Chronic Lymphocytic Leukemia
(Posted: 01/14/2009, Updated: 11/05/2010) - Advanced chronic lymphocytic leukemia patients who received the monoclonal antibody rituximab in addition to standard chemotherapy with fludarabine and cyclophosphamide (FC) had outcomes far better than those patients who received FC alone, according to studies presented December 2008 at the American Society of Hematology meeting.
- Drug Protects Heart in Children Receiving Common Chemotherapy
(Posted: 09/24/2010) - The drug dexrazoxane, which can protect heart tissue from the oxidative damage caused by doxorubicin and other anthracycline drugs, reduced long-term heart damage in children undergoing treatment for high-risk acute lymphoblastic leukemia (ALL) but did not affect treatment efficacy, according to a study published September 15, 2010, in Lancet Oncology.
- Trials Point to More Treatment Options for Chronic Myeloid Leukemia
(Posted: 07/08/2010) - Two studies published online June 5, 2010, in the New England Journal of Medicine found that two second-generation kinase inhibitors outperform imatinib, at least over the short term, in patients with chronic myelogenous leukemia.
- Post-Remission Therapy that Includes All-Trans Retinoic Acid is Effective for Acute Promyelocytic Leukemia
(Posted: 07/02/2010) - A study published online April 14, 2010, in Blood finds that modified consolidation therapy regimens that include all-trans retinoic acid may be less toxic and as effective for patients with low- and medium-risk acute promyelocytic leukemia and may reduce relapse rates for patients with high-risk disease.